(Q82079038)

English

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma

scientific article published on 25 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Hideaki Miyake

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Toshifumi Kurahashi

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Atsushi Takenaka

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Taka-aki Inoue

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Masato Fujisawa

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

25 September 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Urologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

598-603

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Targeted molecular therapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Identifiers

10.1016/J.UROLONC.2008.07.023

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82079038&oldid=2105435135"